Therapeutic drug monitoring in pregnancy

Therapeutic Drug Monitoring

Volumn 34, Issue 5, 2012, Pages 507-511

  Matsui, Doreen M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

adherence; pharmacokinetics; pregnancy; therapeutic drug monitoring

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; LITHIUM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ANTICONVULSANT THERAPY; DISEASE CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA AND VOMITING; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEIZURE;

COST-BENEFIT ANALYSIS; DRUG MONITORING; FEMALE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREGNANCY;

EID: 84866564629     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318261c372     Document Type: Review

References (52)

1. Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs:1976-2008. Am J Obstet Gynecol. 2011;205:51. e1-e8.
2. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol. 2007;3:557-571.
3. Ghiculescu RA. Therapeutic drug monitoring: which drugs, why, when and how to do it. Austr Prescr. 2008;31:42-44.
4. Knott C, Reynolds F. Therapeutic drug monitoring in pregnancy: rationale and current status. Clin Pharmacokinet. 1990;19:425-433.
5. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab. 2009;10:520-529.
6. Dawes M, Chowienczyk PJ. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15:819-826.
7. Little BB. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol. 1999;93:858-868.
8. Loebstein R, Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit. 2002;24:15-22.
9. Adab N. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful? CNS Drugs. 2006; 20:791-800.
10. DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol. 2006;20(4 suppl):54-59.
11. Deligiannidis KM. Therapeutic drug monitoring in pregnant and post-partum women: recommendations for SSRIs, lamotrigine and lithium. J Clin Psychiatry. 2010;71:649-650.
12. Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure. 2008;17:160-165.
13. st century. Does the evidence support definitive outcomes? Clin Phar-macokinet. 1998;34:265-279.
14. Neilsen MJ, Norgaard M, Holland-Fisher P, et al. Self-reported antenatal adherence to medical treatment among pregnant women with Crohn's disease. Aliment Pharmacol Ther. 2010;32:49-58.
15. Nordeng H, Ystrom E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol. 2010;66:207-214.
16. van Trigt AM, Waardenburg CM, Haaijer-Ruskamp FM, et al. Questions about drugs: how do pregnant women solve them? Pharm World Sci. 1994;16:254-259.
17. Hancock RL, Koren G, Einarson A, et al. The effectiveness of teratology information services. Reprod Toxicol. 2007;23:125-132.
18. Tomson J, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet. 2007;46:209-219.
19. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol. 2009;22:157-161.
20. Harden CL, Pennell PB, Koppel BS. Management issues for women with epilepsy: focus on pregnancy (an evidence-based review): III. vitamin K, folic acid, blood levels, and breastfeeding: report of the quality standards subcommitee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50:1247-1255.
21. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy. Neurology. 2008;70:2130-2136.
22. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology. 2004; 63:571-573.
23. Fotopoulou C, Kretz R, Bauer S, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009;85:60-64.
24. Franco V, Mazzucchelli I, Gatti G, et al. Changes in lamotrigine phar-macokinetics during pregnancy and the puerperium. Ther Drug Monit. 2008;30:544-547.
25. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology. 2002;59:251-255.
26. Ohman I, Beck O, Vitols S, et al. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia. 2008;49:1075-1080.
27. Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia. 2009;50:2163-2166.
28. Sabers A. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. Acta Neurol Scand. 2012;126:e1-e4.
29. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology. 2006;67:1497-1499.
30. Petrenaite V, Sabers A, Hansen-Schwartz J. Seizure deterioration in women treated with oxcarbazepine during pregnancy. Epilepsy Res. 2009;84:245-249.
31. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia. 2006;47:504-509.
32. Wegner I, Edelbroek P, deHaan GJ, et al. Drug monitoring of lamotrigine and oxcarbazepine combinations during pregnancy. Epilepsia. 2010;51:2500-2502.
33. López-Fraile IP, Cid AO, Juste AO, et al. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav. 2009;15:372-375.
34. Westin AA, Reimers A, Helde G, et al. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure. 2008;17:192-198.
35. Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilep-sia. 2007;48:1111-1116.
36. Longo B, Forinash AB, Murphy JA. Levetiracetam use in pregnancy. Ann Pharmacother. 2009;43:1692-1695.
37. Westin AA, Nakken KO, Johannessen SI, et al. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia. 2009;50:480-485.
38. Ohman I, Sabers A, de Flon P, et al. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res. 2009;87:124-129.
39. Melville JL, Gavin A, Guo Y, et al. Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. Obstet Gynecol. 2010;116:1064-1070.
40. Markus EM, Miller LJ. The other side of the risk equation: exploring risks of untreated depression and anxiety in pregnancy. J Clin Psychiatry. 2009;70:1314-1315.
41. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499-507.
42. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach part II: clinical pharmacology and therapeutic monitoring. CNS Drugs. 2009;23:331-349.
43. Roustit M, Jlaiel M, Leclercq P, et al. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnancy women. Br J Clin Pharmacol. 2008;66:179-195.
44. Best BM, Capparelli EV. Implications of gender and pregnancy for antiretroviral drug dosing. Curr Opin HIV AIDS. 2008;3:277-282.
45. Siegfried N, van der Merwe L, Brocklehurst P, et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011. No: CD003510. DOI: 10.1002/14651858.CD003510.pub3.
46. Lambert JS, Else LJ, Jackson V, et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med. 2011;12:166-173.
47. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56:412-419.
48. Weinberg A, Harwood JE, McFarland EJ, et al. Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol. 2009;2009:621780.
49. Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol. 2010;37:907-927.
50. Benaboud S, Hirt D, Launay O, et al. Pregnancy-related effects on teno-fovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother. 2012;56:857-862.
51. Benaboud S, Tréluyer JM, Urien S, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother. 2012;56:776-782.
52. Caswell RJ, Phillips D, Chaponda M, et al. Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. Int J STD AIDS. 2011;22:11-14.